4.20
-0.33(-7.28%)
Currency In USD
| Previous Close | 4.53 |
| Open | 4.53 |
| Day High | 4.49 |
| Day Low | 4.16 |
| 52-Week High | 10.25 |
| 52-Week Low | 2.95 |
| Volume | 97,318 |
| Average Volume | 139,736 |
| Market Cap | 234.03M |
| PE | -2.66 |
| EPS | -1.58 |
| Moving Average 50 Days | 4.07 |
| Moving Average 200 Days | 6.11 |
| Change | -0.33 |
If you invested $1000 in Foghorn Therapeutics Inc. (FHTX) since IPO date, it would be worth $231.79 as of May 10, 2025 at a share price of $4.2. Whereas If you bought $1000 worth of Foghorn Therapeutics Inc. (FHTX) shares 3 years ago, it would be worth $426.83 as of May 10, 2025 at a share price of $4.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
GlobeNewswire Inc.
May 05, 2025 11:00 AM GMT
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today annou
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
GlobeNewswire Inc.
May 01, 2025 11:00 AM GMT
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today annou
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
GlobeNewswire Inc.
Apr 28, 2025 8:05 PM GMT
- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab an